Risk adjusted net present value: What is the current valuation of Moderna’s MRNA-3705?

MRNA-3705 is a gene therapy commercialized by Moderna, with a leading Phase II program in Methylmalonic Acidemia.

Edison issues report on BB Biotech (BION) – Biotech Investments

Edison Investment Research Limited Edison issues report on BB Biotech (BION) 26-Jun-2024 / 13:08 GMT/BST The issuer is solely responsible for the content of this

June 27, 2024

MD Anderson launches new institute for advancing cell therapy

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon

November 8, 2024

Phathom notches FDA approval for Voquezna to treat erosive GERD

The FDA on Thursday approved Phathom Pharmaceuticals’ potassium-competitive acid blocker Voquezna (vonoprazan) to treat erosive gastroesophageal reflux disease (GERD), offering a new class of treatment

November 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.